1.15% Less Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Shorted Shares

April 16, 2018 - By Mary Kidd

During 2017 Q4 the big money sentiment decreased to 1.1. That’s change of 0.73, from 2017Q3’s 1.83. 14 investors sold all, 17 reduced holdings as Conatus Pharmaceuticals Inc. ratio dropped. 23 grew positions while 11 funds bought positions. Funds hold 11.71 million shares thus 7.58% more from 2017Q3’s 10.89 million shares.
Vanguard Grp stated it has 1.39M shs or 0% of all its holdings. Financial Bank Of Mellon Corporation stated it has 215,843 shs. Capital Fin Advisers Lc holds 314,955 shs or 0.01% of its capital. Voya Investment Ltd Com invested in 14,517 shs or 0% of the stock. Fny Managed Accounts Limited holds 800 shs or 0% of its capital. 275,593 were accumulated by Morgan Stanley. Stone Ridge Asset Mngmt Lc has invested 0.01% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). California Pub Employees Retirement Sys reported 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Balyasny Asset Limited Company holds 29,727 shs or 0% of its capital. Alliancebernstein L P invested 0% of its capital in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). State Common Retirement Fund reported 24,100 shs. Panagora Asset stated it has 152,975 shs or 0% of all its holdings. Arrowstreet Capital Lp holds 141,700 shs. Geode Capital Management Ltd Liability holds 0% of its capital in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 429,556 shs. State Of Wisconsin Board accumulated 20,000 shs or 0% of the stock.

Change of 1.15% for Conatus Pharmaceuticals Inc (NASDAQ:CNAT)’s short interest was noted. It was issued in April by FINRA the 1.31M short interest on CNAT. The 1.32M previous shares are down with 1.15%. With Average volume 508,700, CNAT’s former position will take 3 days to restore. 4.87% is Conatus Pharmaceuticals Inc float short.

CNAT reached $3.68 on during the last trading session after $0.17 change.Currently Conatus Pharmaceuticals Inc. is uptrending after 12.92% change in last April 16, 2017. CNAT has also 440,875 shares volume. CNAT outperformed by 1.37% the S&P 500.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States.The firm is valued at $110.62 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response.Currently it has negative earnings.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Ratings Coverage

In total 4 analysts cover Conatus Pharmaceuticals (NASDAQ:CNAT). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:CNAT)’s analyst reports since February 8, 2018 according to StockzIntelligence Inc. On Thursday, April 5 the rating was maintained by H.C. Wainwright with “Buy”. On Thursday, March 22 the stock has “Buy” rating by Oppenheimer. In Thursday, March 1 report Oppenheimer initiated the stock with “Buy” rating. On Wednesday, March 7 the stock has “Buy” rating by Oppenheimer.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: